EVOTF
Evotec SE OTC$5.24
Mkt Cap $930.5M
52w Low $4.72
13.4% of range
52w High $8.58
50d MA $6.11
200d MA $7.40
P/E (TTM)
-9.0x
EV/EBITDA
-30.0x
P/B
1.1x
Debt/Equity
0.6x
ROE
-12.3%
P/FCF
-14.8x
RSI (14)
—
ATR (14)
—
Beta
1.24
50d MA
$6.11
200d MA
$7.40
Avg Volume
19
About
Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as diabetes and complications of diabetes, fibrosis, infectious diseases, CNS diseases, oncology, pain and inflammation, immunology, rare diseases, respiratory diseases, and women's health. It …
Recent Earnings
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | 1M% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 8, 2026 | AMC | 0.36 | 0.09 | -74.2% | 5.24 | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | — | — |
| Nov 5, 2025 | AMC | -0.16 | -0.28 | -82.7% | 8.01 | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | — |
| Aug 13, 2025 | AMC | -0.15 | -0.29 | -93.2% | 8.52 | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | -17.3% | — |
| May 6, 2025 | AMC | -0.09 | -0.18 | -105.5% | 8.27 | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | — |
| Apr 17, 2025 | AMC | 0.03 | -0.24 | -868.0% | 8.27 | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | — |
| Nov 6, 2024 | AMC | -0.12 | -0.25 | -100.1% | 6.77 | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +38.0% | — |
| Aug 14, 2024 | AMC | -0.07 | -0.58 | -667.8% | 6.57 | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +8.1% | — |
| May 22, 2024 | AMC | 0.01 | -0.13 | -1612.3% | — | — | — | — | — | — | — | — | — |
| Feb 26, 2024 | AMC | — | -0.10 | — | 14.41 | +0.0% | +0.0% | -4.0% | — | — | — | -29.4% | — |
| Sep 30, 2023 | AMC | -0.06 | -0.23 | -312.0% | — | — | — | — | — | — | — | — | — |
Recent Analyst Ratings
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Aug 30 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $24.33 | $24.33 | +0.0% | +0.0% | +0.0% | +0.0% | -8.8% | -8.8% |
| Jul 11 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $23.60 | $23.37 | -1.0% | -1.0% | -1.0% | -1.0% | -1.0% | -1.0% |
| Jun 22 | Morgan Stanley | Upgrade | Equal Weight → Overweight | — | — | — | — | — | — | — | — | — |
| Jun 15 | BofA Securities | Downgrade | Buy → Neutral | — | $25.13 | $25.13 | +0.0% | +0.0% | -6.1% | -6.1% | — | — |
| Jun 7 | Citigroup | Upgrade | Neutral → Buy | — | — | — | — | — | — | — | — | — |
| Apr 3 | Morgan Stanley | Upgrade | Underweight → Equal Weight | — | $20.65 | $20.65 | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% |
| Nov 15 | Deutsche Bank | Downgrade | Buy → Hold | — | $17.21 | $17.21 | +0.0% | +0.0% | +0.0% | +0.0% | -0.6% | -3.0% |
| Aug 9 | Morgan Stanley | Downgrade | Overweight → Underweight | — | $28.40 | $28.40 | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% |
| Aug 14 | Stifel | Downgrade | Buy → Hold | — | — | — | — | — | — | — | — | — |
Data updated apr 27, 2026 9:34pm
· Source: massive.com